Course: Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients
CME Credits: 1.00
Released: 2022-05-16
Both mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines elicit immune responses consistent with viral neutralization in most immunocompetent persons., Immunosuppressed individuals, such as persons with rheumatic and musculoskeletal diseases (RMDs) and solid organ transplant recipients (SOTRs), have decreased immune responses to these vaccines., Thus, differential vaccine immunogenicity is clinically relevant in ways not seen in immunocompetent persons. This study compares antispike antibody titers after the 2-dose mRNA-1273 and BNT162b2 vaccines in incrementally immunosuppressed patients.
Educational Objective
To identify the key insights or developments described in this article
View Full Course